"These results provide additional confirmation that NNZ-2591 as an oral liquid dose may address the core symptoms of diverse neurodevelopmental disorders, independent of the origin of the underlying genetics"
- Forums
- ASX - By Stock
- Ann: Phase 2 trial shows significant improvements in Angelman
"These results provide additional confirmation that NNZ-2591 as...
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.47 |
Change
-0.260(1.77%) |
Mkt cap ! $1.862B |
Open | High | Low | Value | Volume |
$14.75 | $14.83 | $14.37 | $1.666M | 114.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 186 | $14.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.47 | 84 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 106 | 14.470 |
6 | 432 | 14.460 |
3 | 424 | 14.450 |
4 | 454 | 14.440 |
3 | 478 | 14.430 |
Price($) | Vol. | No. |
---|---|---|
14.490 | 153 | 2 |
14.500 | 1961 | 9 |
14.510 | 592 | 6 |
14.520 | 488 | 4 |
14.530 | 523 | 4 |
Last trade - 11.16am 28/01/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |